Cut-off limits of the GH response to GHRH plus arginine test and IGF-I levels for the diagnosis of GH deficiency in late adolescents and young adults
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objective: To define the appropriate diagnostic cut-off limits for the GH response to GHRH+arginine (ARG) test and IGF-I levels, using receiver operating characteristics (ROC) curve analysis, in late adolescents and young adults. Design and methods: We studied 152 patients with childhood-onset organic hypothalamic–pituitary disease (85 males, age (mean±s.e.m.): 19.2±0.2 years) and 201 normal adolescents as controls (96 males, age: 20.7±0.2 years). Patients were divided into three subgroups on the basis of the number of the other pituitary hormone deficits, excluding GH deficiency (GHD): subgroup A consisted of 35 panhypopituitary patients (17 males, age: 21.2±0.4 years), subgroup B consisted of 18 patients with only one or with no more than two pituitary hormone deficits (7 males, age: 20.2±0.9 years); and subgroup C consisted of 99 patients without any known hormonal pituitary deficits (60 males, age: 18.2±0.2 years). Both patients and controls were lean (body mass index, BMI<25 kg/m 2). Patients in subgroup A were assumed to be GHD, whereas in patients belonging to subgroups B and C the presence of GHD had to be verified. Results: For the GHRH+ARG test, the best pair of highest sensitivity (Se; 100%) and specificity (Sp; 97%) was found choosing a peak GH of 19.0 μg/l. For IGF-I levels, the best pair of highest Se (96.6%) and Sp (74.6%) was found using a cut-off point of 160 μg/l (SDS: −1.3). Assuming 19.0 μg/l to be the cut-off point established for GHRH+ARG test, 72.2% of patients in subgroup B and 39.4% in subgroup C were defined as GHD. In patients belonging to group B and C and with a peak GH response <19 μg/l to the test, IGF-I levels were lower than 160 μg/l (or less than 1.3 SDS) in 68.7 and 41.6% of patients respectively predicting severe GHD in 85.7% of panhypopituitary patients (subgroup A). Conclusions: In late adolescent and early adulthood patients, a GH cut-off limit using the GHRH+ARG test lower than 19.0 μg/l is able to discriminate patients with a suspicion of GHD and does not vary from infancy to early adulthood.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
IRANMANESH, A., LIZARRALDE, G., & VELDHUIS, J. D. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-1081 · Cited by 672
Aimaretti, G., Corneli, G., Razzore, P., Bellone, S., Baffoni, C., Arvat, E., Camanni, F., & Ghigo, E. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.5.4837 · Cited by 272 · cited 1×
“In this study, we aimed to appropriately define using the ROC curve analysis the cut-off levels of the normal GH response to GHRHCARG that is considered as reliable as ITT for the diagnosis of adult GHD (1, 12, 22, 30 ).”
MethodSelf-citationConsensus statement on the management of the GH-treated adolescent in the transition to adult care
Clayton, P. E., Cuneo, R. C., Juul, A., Monson, J. P., Shalet, S. M., & Tauber, M. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01829 · Cited by 270
Darzy, K. H., Aimaretti, G., Wieringa, G., Gattamaneni, H. R., Ghigo, E., & Shalet, S. M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021094 · Cited by 182
Self-citationBonert, V. S., Elashoff, J. D., Barnett, P., & Melmed, S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032213 · Cited by 117
Qu, X.-D., Gaw Gonzalo, I. T., Al Sayed, M. Y., Cohan, P., Christenson, P. D., Swerdloff, R. S., Kelly, D. F., & Wang, C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1450 · Cited by 103
Maghnie, M., Aimaretti, G., Bellone, S., Bona, G., Bellone, J., Baldelli, R., de Sanctis, C., Gargantini, L., Gastaldi, R., Ghizzoni, L., et al. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01873 · Cited by 101 · cited 5×
“In fact, in pediatric age, the most pronounced GH response to a stimulation test occurs in late puberty with GH levels inevitably exceeding 5 mg/l ( 11 ).”
BackgroundMethodResultInfluentialSelf-citation
Cited by
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Sklar, C. A., Antal, Z., Chemaitilly, W., Cohen, L. E., Follin, C., Meacham, L. R., & Murad, M. H. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01175 · Cited by 224
Mazziotti, G., Frara, S., & Giustina, A. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00005 · Cited by 181
Wilkinson, C. W., Pagulayan, K. F., Petrie, E. C., Mayer, C. L., Colasurdo, E. A., Shofer, J. B., Hart, K. L., Hoff, D., Tarabochia, M. A., & Peskind, E. R. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00011 · Cited by 162
Undurti, A., Colasurdo, E. A., Sikkema, C. L., Schultz, J. S., Peskind, E. R., Pagulayan, K. F., & Wilkinson, C. W. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00072 · Cited by 44
Metadata
- Authors
- Corneli, G., Di Somma, C., Prodam, F., Bellone, J., Bellone, S., Gasco, V., Baldelli, R., Rovere, S., Schneider, H. J., Gargantini, L., Gastaldi, R., Ghizzoni, L., Valle, D., Salerno, M., Colao, A., Bona, G., Ghigo, E., Maghnie, M., & Aimaretti, G.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-12
- Volume
- 157
- Issue
- 6
- Pages
- 701-708
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2166024541
- Cited by
- 87
- References
- 8
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.